In a study of 3,737 COVID-19 patients, the researchers found that "Treatment with [[HCQ]]-AZ was associated with a decreased risk of transfer to ICU or death (Hazard ratio (HR) 0.18 0.11–0.27), decreased risk of hospitalization ≥10 days and shorter duration of viral shedding."<ref>https://www.sciencedirect.com/science/article/pii/S1477893920302817</ref> | In a study of 3,737 COVID-19 patients, the researchers found that "Treatment with [[HCQ]]-AZ was associated with a decreased risk of transfer to ICU or death (Hazard ratio (HR) 0.18 0.11–0.27), decreased risk of hospitalization ≥10 days and shorter duration of viral shedding."<ref>https://www.sciencedirect.com/science/article/pii/S1477893920302817</ref> |